{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:05Z","timestamp":1791357245916,"version":"4.3.1"},"reference-count":83,"publisher":"National Institute for Health and Care Research","issue":"17","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["10\/103\/01"],"award-info":[{"award-number":["10\/103\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Imperial Biomedical Research Centre Facility"},{"name":"NIHR Collaboration for Leadership in Applied Health Research and Care East Midlands"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"Background<\/jats:title>No drug treatments are currently licensed for the treatment of borderline personality disorder (BPD). Despite this, people with this condition are frequently prescribed psychotropic medications and often with considerable polypharmacy. Preliminary studies have indicated that mood stabilisers may be of benefit to people with BPD.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine the clinical effectiveness and cost-effectiveness of lamotrigine for people with BPD.<\/jats:p><\/jats:sec>Design<\/jats:title>A two-arm, double-blind, placebo-controlled individually randomised trial of lamotrigine versus placebo. Participants were randomised via an independent and remote web-based service using permuted blocks and stratified by study centre, the severity of personality disorder and the extent of hypomanic symptoms.<\/jats:p><\/jats:sec>Setting<\/jats:title>Secondary care NHS mental health services in six centres in England.<\/jats:p><\/jats:sec>Participants<\/jats:title>Potential participants had to be aged \u2265\u200918 years, meet diagnostic criteria for BPD and provide written informed consent. We excluded people with coexisting psychosis or bipolar affective disorder, those already taking a mood stabiliser, those who spoke insufficient English to complete the baseline assessment and women who were pregnant or contemplating becoming pregnant.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Up to 200\u2009mg of lamotrigine per day or an inert placebo. Women taking combined oral contraceptives were prescribed up to 400\u2009mg of trial medication per day.<\/jats:p><\/jats:sec>Main outcome measures<\/jats:title>Outcomes were assessed at 12, 24 and 52 weeks after randomisation. The primary outcome was the total score on the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) at 52 weeks. The secondary outcomes were depressive symptoms, deliberate self-harm, social functioning, health-related quality of life, resource use and costs, side effects of treatment and adverse events. Higher scores on all measures indicate poorer outcomes.<\/jats:p><\/jats:sec>Results<\/jats:title>Between July 2013 and October 2015 we randomised 276 participants, of whom 195 (70.6%) were followed up 52 weeks later. At 52 weeks, 49 (36%) of those participants prescribed lamotrigine and 58 (42%) of those prescribed placebo were taking it. At 52 weeks, the mean total ZAN-BPD score was 11.3 [standard deviation (SD) 6.6] among those participants randomised to lamotrigine and 11.5 (SD 7.7) among those participants randomised to placebo (adjusted mean difference 0.1, 95% CI \u20131.8 to 2.0;p<\/jats:italic>\u2009=\u20090.91). No statistically significant differences in secondary outcomes were seen at any time. Adjusted costs of direct care for those prescribed lamotrigine were similar to those prescribed placebo.<\/jats:p><\/jats:sec>Limitations<\/jats:title>Levels of adherence in this pragmatic trial were low, but greater adherence was not associated with better mental health.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>The addition of lamotrigine to the usual care of people with BPD was not found to be clinically effective or provide a cost-effective use of resources.<\/jats:p><\/jats:sec>Future work<\/jats:title>Future research into the treatment of BPD should focus on improving the evidence base for the clinical effectiveness and cost-effectiveness of non-pharmacological treatments to help policy-makers make better decisions about investing in specialist treatment services.<\/jats:p><\/jats:sec>Trial registration<\/jats:title>Current Controlled Trials ISRCTN90916365.<\/jats:p><\/jats:sec>Funding<\/jats:title>Funding for this trial was provided by the Health Technology Assessment programme of the National Institute for Health Research (NIHR) and will be published in full inHealth Technology Assessment<\/jats:italic>; Vol. 22, No. 17. See the NIHR Journals Library website for further project information. The Imperial Biomedical Research Centre Facility, which is funded by NIHR, also provided support that has contributed to the research results reported within this paper. Part of Richard Morriss\u2019 salary during the project was paid by NIHR Collaboration for Leadership in Applied Health Research and Care East Midlands.<\/jats:p><\/jats:sec>","DOI":"10.3310\/hta22170","type":"journal-article","created":{"date-parts":[[2018,4,13]],"date-time":"2018-04-13T10:08:10Z","timestamp":1523614090000},"page":"1-68","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["Lamotrigine for people with borderline personality disorder: a RCT"],"prefix":"10.3310","volume":"22","clinical-trial-number":[{"clinical-trial-number":"isrctn90916365","registry":"10.18810\/isrctn","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3137-5772","authenticated-orcid":true,"given":"Mike J","family":"Crawford","sequence":"first","affiliation":[{"name":"Centre for Psychiatry, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3466-4644","authenticated-orcid":true,"given":"Rahil","family":"Sanatinia","sequence":"additional","affiliation":[{"name":"Centre for Psychiatry, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0270-6256","authenticated-orcid":true,"given":"Barbara","family":"Barrett","sequence":"additional","affiliation":[{"name":"Centre for the Economics of Mental and Physical Health, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0298-5398","authenticated-orcid":true,"given":"Gillian","family":"Cunningham","sequence":"additional","affiliation":[{"name":"Tees, Esk and Wear Valleys NHS Foundation Trust, Darlington, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2724-4326","authenticated-orcid":true,"given":"Oliver","family":"Dale","sequence":"additional","affiliation":[{"name":"West London Mental Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1764-5273","authenticated-orcid":true,"given":"Poushali","family":"Ganguli","sequence":"additional","affiliation":[{"name":"Centre for the Economics of Mental and Physical Health, King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0353-4927","authenticated-orcid":true,"given":"Geoff","family":"Lawrence-Smith","sequence":"additional","affiliation":[{"name":"Oxleas NHS Foundation Trust, Dartford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7548-8096","authenticated-orcid":true,"given":"Verity C","family":"Leeson","sequence":"additional","affiliation":[{"name":"Centre for Psychiatry, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6380-5816","authenticated-orcid":true,"given":"Fenella","family":"Lemonsky","sequence":"additional","affiliation":[{"name":"Centre for Psychiatry, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9658-0892","authenticated-orcid":true,"given":"Georgia","family":"Lykomitrou-Matthews","sequence":"additional","affiliation":[{"name":"Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0450-1606","authenticated-orcid":true,"given":"Alan","family":"Montgomery","sequence":"additional","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2910-4121","authenticated-orcid":true,"given":"Richard","family":"Morriss","sequence":"additional","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2368-9464","authenticated-orcid":true,"given":"Jasna","family":"Munjiza","sequence":"additional","affiliation":[{"name":"Central and North West London NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7756-1031","authenticated-orcid":true,"given":"Carol","family":"Paton","sequence":"additional","affiliation":[{"name":"Oxleas NHS Foundation Trust, Dartford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9068-0411","authenticated-orcid":true,"given":"Iwona","family":"Skorodzien","sequence":"additional","affiliation":[{"name":"Division of Psychiatry and Applied Psychology, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2310-3806","authenticated-orcid":true,"given":"Vineet","family":"Singh","sequence":"additional","affiliation":[{"name":"Derbyshire Healthcare NHS Foundation Trust, Derby, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8037-240X","authenticated-orcid":true,"given":"Wei","family":"Tan","sequence":"additional","affiliation":[{"name":"Nottingham Clinical Trials Unit, University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0358-1459","authenticated-orcid":true,"given":"Peter","family":"Tyrer","sequence":"additional","affiliation":[{"name":"Centre for Psychiatry, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2469-9878","authenticated-orcid":true,"given":"Joseph G","family":"Reilly","sequence":"additional","affiliation":[{"name":"Tees, Esk and Wear Valleys NHS Foundation Trust, Darlington, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2018,4]]},"reference":[{"key":"key20180412094404552_ref1-bib1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders.","author":"American Psychiatric Association","year":"1994","edition":"4th edn."},{"key":"key20180412094404552_ref1-bib2","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1192\/bjp.188.5.423","article-title":"Prevalence and correlates of personality disorder in Great Britain","volume":"188","author":"Coid","year":"2006","journal-title":"Br J Psychiatry"},{"key":"key20180412094404552_ref1-bib3","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1176\/ps.2006.57.4.538","article-title":"Personality disorders and unmet needs among psychiatric inpatients","volume":"57","author":"Hayward","year":"2006","journal-title":"Psychiatr Serv"},{"key":"key20180412094404552_ref1-bib4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1192\/bjp.178.1.48","article-title":"Psychiatric and personality disorders in deliberate self-harm patients","volume":"178","author":"Haw","year":"2001","journal-title":"Br J Psychiatry"},{"key":"key20180412094404552_ref1-bib5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0140-6736(04)16770-6","article-title":"Borderline personality disorder","volume":"364","author":"Lieb","year":"2004","journal-title":"Lancet"},{"key":"key20180412094404552_ref1-bib6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1176\/appi.ajp.159.2.276","article-title":"Functional impairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsive personality disorder","volume":"159","author":"Skodol","year":"2002","journal-title":"Am J Psychiatry"},{"key":"key20180412094404552_ref1-bib7","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/PSY.0b013e3181e10c7b","article-title":"Comorbidity and associated severity of borderline personality disorder and physical health conditions in a nationally representative sample","volume":"72","author":"El-Gabalawy","year":"2010","journal-title":"Psychosom Med"},{"key":"key20180412094404552_ref1-bib8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jpsychores.2012.05.001","article-title":"Life expectancy at birth and all-cause mortality among people with personality disorder","volume":"73","author":"Fok","year":"2012","journal-title":"J Psychosom Res"},{"key":"key20180412094404552_ref1-bib9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1192\/bjp.bp.115.173526","article-title":"Impact of personality status on the outcomes and cost of cognitive-behavioural therapy for health anxiety","volume":"209","author":"Sanatinia","year":"2016","journal-title":"Br J Psychiatry"},{"key":"key20180412094404552_ref1-bib10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/pmh.1303","article-title":"Quality of physical health care among patients with personality disorder","volume":"9","author":"Sanatinia","year":"2015","journal-title":"Personal Ment Health"},{"key":"key20180412094404552_ref1-bib11","volume-title":"Borderline Personality Disorder: Treatment and Management","author":"NICE","year":"2009"},{"key":"key20180412094404552_ref1-bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/002076400104700401","article-title":"Experiencing personality disorder: a participative research","volume":"47","author":"Ramon","year":"2001","journal-title":"Int J Soc Psychiatry"},{"key":"key20180412094404552_ref1-bib13","volume-title":"Services for People with Personality Disorder: The Thoughts of Service Users","author":"Haigh","year":"2002"},{"key":"key20180412094404552_ref1-bib14","first-page":"815","article-title":"How nursing staff respond to the label \u2018borderline personality disorder\u2019","volume":"40","author":"Gallop","year":"1989","journal-title":"Hosp Community Psychiatry"},{"key":"key20180412094404552_ref1-bib15","first-page":"CD005652","article-title":"Psychological therapies for people with borderline personality disorder","volume":"1","author":"Binks","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"key20180412094404552_ref1-bib16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.cpr.2009.12.002","article-title":"Non-completion of personality disorder treatments: a systematic review of correlates, consequences, and interventions","volume":"30","author":"McMurran","year":"2010","journal-title":"Clin Psychol Rev"},{"key":"key20180412094404552_ref1-bib17","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1600-0447.2008.01306.x","article-title":"Engagement and retention in specialist services for people with personality disorder","volume":"119","author":"Crawford","year":"2009","journal-title":"Acta Psychiatr Scand"},{"key":"key20180412094404552_ref1-bib18","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1600-0447.2011.01728.x","article-title":"Medication prescribed to people with personality disorder: the influence of patient factors and treatment setting","volume":"124","author":"Crawford","year":"2011","journal-title":"Acta Psychiatr Scand"},{"key":"key20180412094404552_ref1-bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1192\/bjp.bp.108.062984","article-title":"Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials","volume":"196","author":"Lieb","year":"2010","journal-title":"Br J Psychiatry"},{"key":"key20180412094404552_ref1-bib20","doi-asserted-by":"crossref","first-page":"g5378","DOI":"10.1136\/bmj.g5378","article-title":"Are mood stabilisers helpful in treatment of borderline personality disorder?","volume":"349","author":"Crawford","year":"2014","journal-title":"BMJ"},{"key":"key20180412094404552_ref1-bib21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.seizure.2004.02.005","article-title":"Safety of newer generation anti-epileptic drugs in non-accidental overdose: an Irish population study","volume":"14","author":"Sukumaran","year":"2005","journal-title":"Seizure"},{"key":"key20180412094404552_ref1-bib22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.yebeh.2007.08.015","article-title":"Antiepileptic drug exposure and major congenital malformations: the role of pregnancy registries","volume":"11","author":"Tomson","year":"2007","journal-title":"Epilepsy Behav"},{"key":"key20180412094404552_ref1-bib23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0074-7742(08)00011-1","article-title":"Antiepileptic drug teratogenesis: what are the risks for congenital malformations and adverse cognitive outcomes?","volume":"83","author":"Harden","year":"2008","journal-title":"Int Rev Neurobiol"},{"key":"key20180412094404552_ref1-bib24","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa0803531","article-title":"Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs","volume":"360","author":"Meador","year":"2009","journal-title":"N Engl J Med"},{"key":"key20180412094404552_ref1-bib25","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1192\/bjp.bp.107.048504","article-title":"Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials","volume":"194","author":"Geddes","year":"2009","journal-title":"Br J Psychiatry"},{"key":"key20180412094404552_ref1-bib26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2215-0366(15)00450-2","article-title":"Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2\u2009\u00d7\u20092 factorial randomised trial","volume":"3","author":"Geddes","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"key20180412094404552_ref1-bib27","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/01.jcp.0000088915.02635.e8","article-title":"Potential mechanisms of action of lamotrigine in the treatment of bipolar disorders","volume":"23","author":"Ketter","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"key20180412094404552_ref1-bib28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/0269881105051540","article-title":"Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study","volume":"19","author":"Tritt","year":"2005","journal-title":"J Psychopharmacol"},{"key":"key20180412094404552_ref1-bib29","first-page":"270","article-title":"A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder","volume":"24","author":"Reich","year":"2009","journal-title":"Int Clin Psychopharmacol"},{"key":"key20180412094404552_ref1-bib30","volume-title":"British National Formulary 74","author":"British National Formulary","year":"2017"},{"key":"key20180412094404552_ref1-bib31","volume-title":"Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II), Version 2.0","author":"First","year":"1994"},{"key":"key20180412094404552_ref1-bib32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1521\/pedi.1997.11.3.279","article-title":"Interrater reliability and internal consistency of the structured clinical interview for DSM-IV axis II personality disorders (SCID-II), version 2.0","volume":"11","author":"Maffei","year":"1997","journal-title":"J Pers Disord"},{"key":"key20180412094404552_ref1-bib33","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1176\/ajp.153.12.1593","article-title":"Establishing the severity of personality disorder","volume":"153","author":"Tyrer","year":"1996","journal-title":"Am J Psychiatry"},{"key":"key20180412094404552_ref1-bib34","volume-title":"International Personality Disorder Examination (IPDE) Manual","author":"Loranger","year":"1995"},{"key":"key20180412094404552_ref1-bib35","volume-title":"Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version","author":"First","year":"2002"},{"key":"key20180412094404552_ref1-bib36","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bdi.12101","article-title":"Transcultural validity of the Hypomania Checklist-32 (HCL-32) in patients with major depressive episodes","volume":"15","author":"Gamma","year":"2013","journal-title":"Bipolar Disord"},{"key":"key20180412094404552_ref1-bib37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1521\/pedi.17.3.233.22147","article-title":"Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology","volume":"17","author":"Zanarini","year":"2003","journal-title":"J Pers Disord"},{"key":"key20180412094404552_ref1-bib38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1053\/comp.2002.33497","article-title":"STEPPS: a cognitive-behavioral systems-based group treatment for outpatients with borderline personality disorder \u2013 a preliminary report","volume":"43","author":"Blum","year":"2002","journal-title":"Compr Psychiatry"},{"key":"key20180412094404552_ref1-bib39","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.4088\/JCP.08m04138yel","article-title":"A dose comparison of olanzapine for the treatment of borderline personality disorder: a 12-week randomized, double-blind, placebo-controlled study","volume":"72","author":"Zanarini","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"key20180412094404552_ref1-bib40","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1176\/appi.ajp.2007.07071079","article-title":"Systems Training for Emotional Predictability and Problem Solving (STEPPS) for outpatients with borderline personality disorder: a randomized controlled trial and 1-year follow-up","volume":"165","author":"Blum","year":"2008","journal-title":"Am J Psychiatry"},{"key":"key20180412094404552_ref1-bib41","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression","volume":"4","author":"Beck","year":"1961","journal-title":"Arch Gen Psychiatry"},{"key":"key20180412094404552_ref1-bib42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0272-7358(88)90050-5","article-title":"Psychometric properties of the Beck Depression Inventory: twenty-five years later","volume":"8","author":"Beck","year":"1988","journal-title":"Clin Psychol Rev"},{"key":"key20180412094404552_ref1-bib43","doi-asserted-by":"crossref","DOI":"10.4324\/9780203945902","volume-title":"Cognitive Therapy for Personality Disorders: A Guide for Clinicians","author":"Davidson","year":"2007","edition":"2nd edn"},{"key":"key20180412094404552_ref1-bib44","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1521\/pedi.2006.20.5.466","article-title":"The cost-effectiveness of cognitive behavior therapy for borderline personality disorder: results from the BOSCOT trial","volume":"20","author":"Palmer","year":"2006","journal-title":"J Pers Disord"},{"key":"key20180412094404552_ref1-bib45","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/0020764005057391","article-title":"The Social Functioning Questionnaire: a rapid and robust measure of perceived functioning","volume":"51","author":"Tyrer","year":"2005","journal-title":"Int J Soc Psychiatry"},{"key":"key20180412094404552_ref1-bib46","volume-title":"Quality of Life and Pharmacoeconomics in Clinical Trials","author":"Kind","year":"1996","edition":"2nd edn."},{"key":"key20180412094404552_ref1-bib47","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.eurpsy.2008.11.001","article-title":"The EQ-5D: a useful quality of life measure in borderline personality disorder?","volume":"24","author":"van Asselt","year":"2009","journal-title":"Eur Psychiatry"},{"key":"key20180412094404552_ref1-bib48","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1046\/j.1360-0443.2002.00185.x","article-title":"The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility","volume":"97","author":"WHO ASSIST Working Group","year":"2002","journal-title":"Addiction"},{"key":"key20180412094404552_ref1-bib49","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1080\/09595230500170266","article-title":"Validation of the World Health Organization Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): report of results from the Australian site","volume":"24","author":"Newcombe","year":"2005","journal-title":"Drug Alcohol Rev"},{"key":"key20180412094404552_ref1-bib50","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1192\/bjp.bp.112.117762","article-title":"Joint crisis plans for people with borderline personality disorder: feasibility and outcomes in a randomised controlled trial","volume":"202","author":"Borschmann","year":"2013","journal-title":"Br J Psychiatry"},{"key":"key20180412094404552_ref1-bib51","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","article-title":"Concurrent and predictive validity of a self-reported measure of medication adherence","volume":"24","author":"Morisky","year":"1986","journal-title":"Med Care"},{"key":"key20180412094404552_ref1-bib52","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1046\/j.1365-2125.2000.00244.x","article-title":"Compliance with tricyclic antidepressants: the value of four different methods of assessment","volume":"50","author":"George","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"key20180412094404552_ref1-bib53","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s13063-015-0823-x","article-title":"Lamotrigine versus inert placebo in the treatment of borderline personality disorder: study protocol for a randomized controlled trial and economic evaluation","volume":"16","author":"Crawford","year":"2015","journal-title":"Trials"},{"key":"key20180412094404552_ref1-bib54","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jad.2005.05.011","article-title":"The HCL-32: towards a self-assessment tool for hypomanic symptoms in outpatients","volume":"88","author":"Angst","year":"2005","journal-title":"J Affect Disord"},{"key":"key20180412094404552_ref1-bib55","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Moher","year":"2010","journal-title":"BMJ"},{"key":"key20180412094404552_ref1-bib56","volume-title":"Guide to the Methods of Technology Appraisal","author":"NICE","year":"2013"},{"key":"key20180412094404552_ref1-bib57","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.eurpsy.2007.04.001","article-title":"The cost of borderline personality disorder: societal cost of illness in BPD-patients","volume":"22","author":"van Asselt","year":"2007","journal-title":"Eur Psychiatry"},{"key":"key20180412094404552_ref1-bib58","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1017\/S1121189X00001019","article-title":"Cost-effectiveness of nidotherapy for comorbid personality disorder and severe mental illness: randomized controlled trial","volume":"18","author":"Ranger","year":"2009","journal-title":"Epidemiol Psichiatr Soc"},{"key":"key20180412094404552_ref1-bib59","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2015","edition":"69th edn."},{"key":"key20180412094404552_ref1-bib60","volume-title":"Unit Costs of Health & Social Care 2015","author":"Curtis","year":"2016"},{"key":"key20180412094404552_ref1-bib61","volume-title":"A Social Tariff for EuroQoL: Results from a UK General Population Survey","author":"Dolan","year":"1995"},{"key":"key20180412094404552_ref1-bib62","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hec.944","article-title":"Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility","volume":"14","author":"Manca","year":"2005","journal-title":"Health Econ"},{"key":"key20180412094404552_ref1-bib63","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-4541-9","volume-title":"An Introduction to the Bootstrap","author":"Efron","year":"1993"},{"key":"key20180412094404552_ref1-bib64","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1136\/bmj.320.7243.1197","article-title":"How should cost data in pragmatic randomised controlled trials be analysed?","volume":"320","author":"Thompson","year":"2000","journal-title":"BMJ"},{"key":"key20180412094404552_ref1-bib65","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/hec.4730030505","article-title":"Costs, effects and C\/E-ratios alongside a clinical trial","volume":"3","author":"van Hout","year":"1994","journal-title":"Health Econ"},{"key":"key20180412094404552_ref1-bib66","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1002\/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P","article-title":"Analysis of cost data in randomized trials: an application of the non-parametric bootstrap","volume":"19","author":"Barber","year":"2000","journal-title":"Stat Med"},{"key":"key20180412094404552_ref1-bib67","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/hec.903","article-title":"Cost-effectiveness acceptability curves \u2013 facts, fallacies and frequently asked questions","volume":"13","author":"Fenwick","year":"2004","journal-title":"Health Econ"},{"key":"key20180412094404552_ref1-bib68","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"Declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"key20180412094404552_ref1-bib69","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/archpsyc.1994.03950030051005","article-title":"The International Personality Disorder Examination. The World Health Organization\/Alcohol, Drug Abuse and Mental Health Administration international pilot study of personality disorders","volume":"51","author":"Loranger","year":"1994","journal-title":"Arch Gen Psychiatr"},{"key":"key20180412094404552_ref1-bib70","volume-title":"The Medical Dictionary for Regulatory Activities","author":"MedDRA"},{"issue":"52","key":"key20180412094404552_ref1-bib71","doi-asserted-by":"crossref","DOI":"10.3310\/hta20520","article-title":"Psychoeducation with problem-solving (PEPS) therapy for adults with personality disorder: a pragmatic randomised controlled trial to determine the clinical effectiveness and cost-effectiveness of a manualised intervention to improve social functioning","volume":"20","author":"McMurran","year":"2016","journal-title":"Health Technol Assess"},{"key":"key20180412094404552_ref1-bib72","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.4088\/JCP.14m09228","article-title":"The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services","volume":"76","author":"Paton","year":"2015","journal-title":"J Clin Psychiatry"},{"key":"key20180412094404552_ref1-bib73","volume-title":"Borderline Personality Disorder: The NICE Guideline on Treatment and Management","author":"NICE","year":"2009"},{"key":"key20180412094404552_ref1-bib74","first-page":"CD005652","article-title":"Psychological therapies for people with borderline personality disorder","volume":"8","author":"Stoffers","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"key20180412094404552_ref1-bib75","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/archpsyc.63.6.649","article-title":"Outpatient psychotherapy for borderline personality disorder: randomized trial of schema-focused therapy vs. transference-focused psychotherapy","volume":"63","author":"Giesen-Bloo","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"key20180412094404552_ref1-bib76","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1192\/bjp.bp.116.184366","article-title":"A randomized controlled trial of democratic therapeutic community treatment for personality disorder","volume":"210","author":"Pearce","year":"2017","journal-title":"Br J Psychiatry"},{"key":"key20180412094404552_ref1-bib77","first-page":"1","article-title":"Medicines related to valproate: risk of abnormal pregnancy outcomes","volume":"8","author":"Medicines and Healthcare Products Regulatory Agency","year":"2015","journal-title":"Drug Safety Update"},{"key":"key20180412094404552_ref1-bib78","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1176\/appi.ajp.2009.09010039","article-title":"A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder","volume":"166","author":"McMain","year":"2009","journal-title":"Am J Psychiatry"},{"key":"key20180412094404552_ref1-bib79","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1176\/appi.ajp.2009.09040539","article-title":"Randomized controlled trial of outpatient mentalization-based treatment versus structured clinical management for borderline personality disorder","volume":"166","author":"Bateman","year":"2009","journal-title":"Am J Psychiatry"},{"key":"key20180412094404552_ref1-bib80","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1017\/S1092852900027279","article-title":"Self-help and Internet-guided interventions in depression and anxiety disorders: a systematic review of meta-analyses","volume":"14","author":"van\u2019t Hof","year":"2009","journal-title":"CNS Spectr"},{"key":"key20180412094404552_ref1-bib81","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1176\/appi.ps.53.3.348-a","article-title":"Clozapine and borderline personality disorder","volume":"53","author":"Parker","year":"2002","journal-title":"Psychiatr Serv"},{"key":"key20180412094404552_ref1-bib82","first-page":"125","article-title":"A case series of clozapine for borderline personality disorder","volume":"25","author":"Frogley","year":"2013","journal-title":"Ann Clin Psychiatry"},{"key":"key20180412094404552_ref1-bib83","volume-title":"NHS Reference Costs 2015","author":"Department of Health and Social Care","year":"2016"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta22170\/hta22170.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2003384","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta22170\/hta22170.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2013430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T15:43:06Z","timestamp":1692114186000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta22170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":83,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2018,4]]}},"alternative-id":["10.3310\/hta22170"],"URL":"https:\/\/doi.org\/10.3310\/hta22170","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}